Eurogin is part of the Informa Markets Division of Informa PLC


Early bird rates available! Secure your pass now!

EUROGIN Program Highlights

High-level Scientific Program

A full overview of current scientific developments in the field of cervical cancer and other HPV related diseases.

EUROGIN focuses on translating scientific and evidence-based research into clinical practice by offering a high quality and innovative scientific program drawn up by outstanding international leaders from the academic sector as well as professional and patient organizations. 

The program aims to foster future advancements by providing fundamental insights to physicians and young researchers.

What not to miss at EUROGIN

Nordic Countries Workshop

Wednesday, March 13, 2024

For the 2024 edition of EUROGIN, we have a half-day local workshop that will not only focus on the latest research but also on health policies within the Nordic Countries.

Coordinators: J. Bonde • J. Dillner

HPV and Head & Neck Forum

March 14-15, 2024

The EUROGIN HPV and Head & Neck Cancer Forum will highlight recent advances and areas of active research in the field of HPV-related head and neck cancers.

Coordinators: C. J. Brenner • J. P. Klussmann • K. Lang Kuhs (USA) • S. Virani

Screening for HPV-vaccinated cohorts: country-specific experience

Cohorts vaccinated through childhood HPV vaccination have entered the screening programmes in many countries. With the remarkable protection gained from the HPV vaccines, the significantly lower level of HPV circulation and less cervical lesions have impacted the cervical screening. 

This session is dedicated to screening practices and outcomes for HPV-vaccinated cohorts from different countries. We would like to communicate about what impact in each of the programmes has observed, challenges that our current programmes are facing, and potential changes might be necessary to accommodate the effect of HPV vaccination.

Chairs: J. Lei (Sweden) • P. Sasieni (UK)

HPV genital diseases and treatment during pregnancy

Managing HPV during pregnancy requires careful consideration of the potential risks and benefits of various diagnostic and treatment approaches. The risk of progression of CIN 2-3 to cancer should be balanced against the fear of complications of conization.

Here are some key points that will be discussed during that session: 

  • The transmission of HPV from mother to foetus is a concern. It’s essential to understand the risk factors, the likelihood of transmission, and how it may impact the newborn.
  • Investigation of abnormal PAP Smear during pregnancy will be discussed, the challenge of colposcopy, which requires expertise, and the indication for performing cervical biopsy.
  • We will present controversies about conization during pregnancy and studies that describe the outcome of those operations.
  • We will share the options available for treating cervical cancer while considering the well-being of both the pregnant woman and the fetus.

Chairs: K. Louvanto • E. Siegler

The EUROGIN congress offers a full overview of current scientific developments in the field of cervical cancer and other HPV related diseases control with a program informed by leading scientists.